Verona Pharma VRNA 2022 Ensifentrine COPD Investor Presentation

Verona Pharma presents ensifentrine, a Phase 3 first-in-class dual PDE3/PDE4 inhibitor candidate for COPD maintenance treatment targeting a $10.5B US market with over 1 million symptomatic patients. The presentation outlines the drug's novel mechanism of action, demonstrated efficacy from Phase 2b trials, favorable safety profile, and commercial strategy focused on pulmonologists and Medicare Part B reimbursement.